Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL712106

O=C(O)C(F)(F)F.O=C(O)c1cnc2[nH]c(-c3ccc(OCc4ccccc4)cc3OCc3ccccc3)nc2c1

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 1/20 0.43
CSNK2A1 P68400 1/20 0.43
P2RY14 Q15391 1/20 0.40
CHEK2 O96017 1/20 0.40
MRGPRX4 Q96LA9 3/20 0.40
NR4A2 P43354 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40
SRD5A2 P31213 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
NR4A1 P22736 1/20 0.40
NR4A3 Q92570 1/20 0.40
GCK P35557 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10206508 0.94 CSNK2A2 (0.47) CSNK2A2CSNK2A1P2RY14CHEK2MRGPRX4
Trifluoroacetic Acid SCHEMBL710782 0.90 MAPT (0.41) CSNK2A2CSNK2A1P2RY14CHEK2KDM4E
Trifluoroacetic Acid SCHEMBL710612 0.90 MAOB (0.49) CSNK2A2CSNK2A1ALDH1A1HPGDMEN1
SCHEMBL712107 0.89 CHEK2 (0.39) CSNK2A2CSNK2A1CHEK2KDM4EALDH1A1
SCHEMBL9071800 0.87 MAOB (0.46) CSNK2A2CSNK2A1P2RY14CHEK2KDM4E
Trifluoroacetic Acid SCHEMBL711971 0.86 CYP3A4 (0.43) CHEK2KDM4EALDH1A1CYP1A2CYP2C9
SCHEMBL711611 0.85 GCK (0.47) CSNK2A2CSNK2A1P2RY14CHEK2MRGPRX4
SCHEMBL10206496 0.84 MAOB (0.51) CSNK2A2CSNK2A1ALDH1A1HPGDMEN1
Trifluoroacetic Acid SCHEMBL710837 0.83 MAOB (0.46) ALDH1A1HPGDMEN1KMT2A
Trifluoroacetic Acid SCHEMBL710810 0.82 MCL1 (0.41) CHEK2KDM4EGCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK CSNK2A2 350/4885CSNK2A1 326/4885P2RY14 1121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.